Gideon Hirschfield

Aug 15, 2024 | hcplive.com | Nancy Reau |Palak J Trivedi |Gideon Hirschfield |MB BChir

In recognition of the US Food and Drug Administration accelerated approval of Gilead's seladelpar (Livdelzi) and other recent evolutions in primary biliary cholangitis (PBC), the latest HCPLive Special Report spotlights a conversation between a trio of subject matter experts on the latest advancements in PBC and their implications for disease management.

Jun 27, 2024 | bmjopen.bmj.com | Nasir Hussain |Christopher Ma |Gideon Hirschfield |Martine Walmsley

A list of all possible outcomes will be identified by a comprehensive systematic literature search of the following databases: Medline, EMBASE and Cochrane Library. This will be conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.34 Studies published in English and from the last 40 years (January 1983 to January 2024) will be included, to ensure that the data captured reflects both historic and contemporary knowledge about PSC.

May 1, 2024 | fis.uke.de | Aldo J. Montano-Loza |Ellina Lytvyak |Gideon Hirschfield |Bettina Hansen

BACKGROUND & AIMS: Recurrent primary biliary cholangitis (rPBC) develops in approximately 30% of patients and negatively impacts graft and overall patient survival after liver transplantation (LT). There is a lack of data regarding the response rate to ursodeoxycholic acid (UDCA) in rPBC. We evaluated a large, international, multi-center cohort to assess the performance of PBC scores in predicting the risk of graft and overall survival after LT in patients with rPBC.

Apr 30, 2024 | healio.com | Cory Perla |Gideon Hirschfield |MB BChir |Heather Biele

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The liver’s production of bile acids is interwoven with the gut’s diverse microbial community. Despite treatment advances, the microbiome’s impact poses challenges in developing personalized therapies.

Mar 29, 2023 | emjreviews.com | Cynthia Levy |Gideon Hirschfield |Andreas Kremer |Kidist K. Yimam

Itch TreatmentItch progressed in intensity (NRS: 8−9/10) and how much it affected the patient’s QoL. There was no benefit from antihistamines and an anion-exchange resin was not tolerated due to the unpleasant taste, so it was terminated by the patient. Rifampicin was not prescribed due to drug-drug interactions with oral contraceptives, which the patient wished to remain taking, and a fibrate brought mild benefit but was not tolerated due to myopathy.